OneVentures are searching for the healthcare companies of tomorrow


OneVentures and leading US venture capitalist Jim Scopa are gearing up for an Australian roadshow to look for investment opportunities – and local companies are invited to express interest in meeting.

OneVentures $170 million Biomedical Translational Fund team will join with Jim Scopa, formerly of MPM Capital, a USD$2.6 billion US-based venture capital firm, and currently a fellow at Stanford University, to run breakfast meetings in Sydney (7 September), Melbourne (8 September) and Brisbane (11 September).

Over breakfast, Jim will present the US perspective on the healthcare market and how emerging Australian healthcare sector companies need to position themselves to succeed on the global stage, while attendees can get to know the OneVentures healthcare team at the panel discussion.

Selected one-on-one meetings will be arranged with the OneVentures team to allow companies to pitch an investable company or project in medical devices, diagnostics or pharmaceuticals.

Those seeking a one-on-one meeting are requested to send:

  • Company/project name;
  • Contact details;
  • A 200-word description of the company including target market, solution overview and stage of development, including a summary of capital raised to date (if any) and capital required (if known);
  • 10-slide investor deck.

OneVentures is an Australian venture capital firm with $320 million under management, has delivered exit value to investors of $1.5billion including four Nasdaq companies. Existing healthcare sector portfolio companies include Hatchtech, Vaxxas, Clinical Genomics Technologies and Prota Therapeutics.

OneVentures recently launched its $170M Healthcare Fund III, which is focused on investing in companies with products that have reached clinical proof of concept, with at least Phase 1 or equivalent trial results; a clear commercial, regulatory and reimbursement pathway; and well defined value inflection and exit points on deal entry.

The Fund is seeking to invest $10 to $20 million in Australian domiciled companies commercialising medical devices, drugs in clinical development or diagnostics.

To express interest or find out more, see: